Winning entry in art competition depictsbeauty, wholeness despite mastectomy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Architect Nikko Shabtai, of Beverly Hills, Calif., took fi rst prize in the Oncology on Canvas event, sponsored by Eli Lilly in partnership with the National Coalition for Cancer Survivorship.

Architect Nikko Shabtai, of Beverly Hills, Calif., took first prize in the Oncology on Canvas event, sponsored by Eli Lilly in partnership with the National Coalition for Cancer Survivorship.

Mr. Shabtai used a painter’s knife, rather than a paintbrush, to create “As I Am, Beautiful and Whole,” which won the Best of Exhibition trophy and an award of $10,000 donated to the Cancer Schmancer Foundation on his behalf.

Mr. Shabtai’s acrylic painting portrays a woman who appears to have undergone a mastectomy. “I was painting the model in my painting workshop when I picked up my knife instead of a brush and painted her without a breast,” Mr. Shabtai explained in a written statement. He said he realized that his inspiration for this piece was the breast cancer diagnosis, and subsequent mastectomy, that a family member had recently experienced.

 

In all, 19 winners were selected in the Oncology on Canvas: Expressions of a Cancer Journey Art Competition and Exhibition, with 26 prizes given to 22 cancer charities.

Elizabeth Menges of Boston took home second prize for a series of six small oil paintings that detail the morning dressing routine of a breast cancer survivor.

New York-based breast cancer survivor Barbara E. Litke and artist Nash Hyon, of Wilton, Conn., tied for third place.

 

 

 

 

 

 

Recent Videos
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
7 experts are featured in this series.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Related Content